Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.
Bottom Line: Grade 3/4 adverse events in more than two patients were lymphopenia (50%) and neutropenia (15%).The pharmacokinetic profile was similar to that observed in the previous studies in the USA.These results show that brentuximab vedotin has an acceptable safety profile and promising antitumor activity in the Japanese population.
Affiliation: Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan.Show MeSH
Related in: MedlinePlus
Mentions: Figure 1 shows the maximum tumor reduction in individual patients in phase II. Five patients (56%) with HL and four (80%) with sALCL had a best response of CR. In this part, five patients with HL had not previously undergone ASCT. Of these, four patients (80%) achieved an OR, including two CRs. Furthermore, three patients had primary cutaneous ALCL that had transformed to sALCL, and they all had a CR.
Affiliation: Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan.